America Great Health (AAGH)
USD 0.0
(-18.18%)
USD 0.0
(-18.18%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 661.23 Thousand USD | -79.66% |
| 2022 | 3.25 Million USD | 1002.12% |
| 2021 | 294.91 Thousand USD | 511.14% |
| 2020 | 48.25 Thousand USD | 3.18% |
| 2019 | 46.77 Thousand USD | -19.57% |
| 2018 | 58.14 Thousand USD | 20.23% |
| 2017 | 48.36 Thousand USD | -96.44% |
| 2016 | 1.35 Million USD | 110.62% |
| 2015 | 644.15 Thousand USD | 6.36% |
| 2014 | 605.61 Thousand USD | 431.24% |
| 2013 | 114 Thousand USD | 89.04% |
| 2012 | 60.3 Thousand USD | 173.81% |
| 2011 | 22.02 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 236.52 Thousand USD | 167.05% |
| 2024 Q3 | 216.37 Thousand USD | -8.52% |
| 2024 Q1 | 88.56 Thousand USD | -61.86% |
| 2023 Q4 | 232.23 Thousand USD | 53.8% |
| 2023 FY | 661.23 Thousand USD | -79.66% |
| 2023 Q1 | 152.65 Thousand USD | -92.15% |
| 2023 Q2 | 125.33 Thousand USD | -17.9% |
| 2023 Q3 | 150.99 Thousand USD | 20.47% |
| 2022 Q2 | 358.11 Thousand USD | 20.15% |
| 2022 FY | 3.25 Million USD | 1002.12% |
| 2022 Q4 | 1.94 Million USD | 199.31% |
| 2022 Q3 | 649.64 Thousand USD | 81.41% |
| 2022 Q1 | 298.06 Thousand USD | 102.26% |
| 2021 Q3 | 13.46 Million USD | 38776.62% |
| 2021 Q4 | -13.2 Million USD | -198.08% |
| 2021 FY | 294.91 Thousand USD | 511.14% |
| 2021 Q1 | 1174.00 USD | -96.61% |
| 2021 Q2 | 34.63 Thousand USD | 2850.51% |
| 2020 FY | 48.25 Thousand USD | 3.18% |
| 2020 Q4 | 34.63 Thousand USD | 2237.04% |
| 2020 Q3 | 1482.00 USD | -85.16% |
| 2020 Q2 | 9986.00 USD | 363.82% |
| 2020 Q1 | 2153.00 USD | -75.66% |
| 2019 Q4 | 8844.00 USD | 17.43% |
| 2019 Q3 | 7531.00 USD | -69.3% |
| 2019 FY | 46.77 Thousand USD | -19.57% |
| 2019 Q1 | 5868.00 USD | -72.15% |
| 2019 Q2 | 24.52 Thousand USD | 318.0% |
| 2018 Q2 | 15.07 Thousand USD | 16.81% |
| 2018 FY | 58.14 Thousand USD | 20.23% |
| 2018 Q4 | 21.07 Thousand USD | 131.57% |
| 2018 Q3 | 9099.00 USD | -39.64% |
| 2018 Q1 | 12.9 Thousand USD | 126.68% |
| 2017 Q2 | -860.69 Thousand USD | -1735.32% |
| 2017 Q1 | 52.63 Thousand USD | -82.38% |
| 2017 Q3 | 12.12 Thousand USD | 101.41% |
| 2017 Q4 | -48.36 Thousand USD | -498.93% |
| 2017 FY | 48.36 Thousand USD | -96.44% |
| 2016 Q2 | 182.83 Thousand USD | -73.76% |
| 2016 Q3 | 178.46 Thousand USD | -2.39% |
| 2016 Q1 | 696.66 Thousand USD | 317.26% |
| 2016 Q4 | 298.76 Thousand USD | 67.41% |
| 2016 FY | 1.35 Million USD | 110.62% |
| 2015 Q2 | 159.62 Thousand USD | 0.52% |
| 2015 Q4 | 166.95 Thousand USD | 5.15% |
| 2015 Q3 | 158.78 Thousand USD | -0.53% |
| 2015 Q1 | 158.79 Thousand USD | -60.7% |
| 2015 FY | 644.15 Thousand USD | 6.36% |
| 2014 Q3 | 151.69 Thousand USD | 204.05% |
| 2014 Q1 | 65.21 Thousand USD | -6.49% |
| 2014 Q4 | 404.03 Thousand USD | 166.35% |
| 2014 FY | 605.61 Thousand USD | 431.24% |
| 2014 Q2 | 49.89 Thousand USD | -23.5% |
| 2013 Q2 | 18.19 Thousand USD | 50.39% |
| 2013 Q4 | 69.74 Thousand USD | 416.83% |
| 2013 Q3 | 13.49 Thousand USD | -25.82% |
| 2013 Q1 | 12.09 Thousand USD | -75.39% |
| 2013 FY | 114 Thousand USD | 89.04% |
| 2012 Q2 | 6728.00 USD | 501.79% |
| 2012 Q3 | 4417.00 USD | -34.35% |
| 2012 Q1 | 1118.00 USD | -39.53% |
| 2012 Q4 | 49.16 Thousand USD | 1012.97% |
| 2012 FY | 60.3 Thousand USD | 173.81% |
| 2011 FY | 22.02 Thousand USD | 0.0% |
| 2011 Q4 | 1849.00 USD | 496.45% |
| 2011 Q3 | 310.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | 92.865% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 97.795% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 99.015% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | 95.826% |
| Better Therapeutics, Inc. | 38.26 Million USD | 98.272% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 98.375% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | 94.664% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 98.046% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 98.079% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 99.39% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | 33.398% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 97.971% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 98.592% |
| Innovation1 Biotech Inc. | 1.21 Million USD | 45.564% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | 96.684% |
| Molecular Templates, Inc. | 63.09 Million USD | 98.952% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | 95.254% |
| NexImmune, Inc. | 28.16 Million USD | 97.653% |
| Orgenesis Inc. | 45.75 Million USD | 98.555% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 97.422% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -800.665% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | 95.904% |
| Scopus BioPharma Inc. | 11.71 Million USD | 94.356% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 99.836% |
| Statera Biopharma, Inc. | 28.82 Million USD | 97.706% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | 96.507% |
| Trevena, Inc. | 38.41 Million USD | 98.279% |
| Vaxxinity, Inc. | 56.05 Million USD | 98.82% |
| Vaccinex, Inc. | 23.45 Million USD | 97.181% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | 36.844% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 98.696% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | 90.91% |